See more : Harte Hanks, Inc. (HRTH) Income Statement Analysis – Financial Results
Complete financial analysis of Charles River Laboratories International, Inc. (CRL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Charles River Laboratories International, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- M. K. Proteins Limited (MKPL.BO) Income Statement Analysis – Financial Results
- Coca-Cola Içecek Anonim Sirketi (CCOLA.IS) Income Statement Analysis – Financial Results
- Kontour (Xi’an) Medical Technology Co., Ltd. (688314.SS) Income Statement Analysis – Financial Results
- Currys plc (CURY.L) Income Statement Analysis – Financial Results
- China United Venture Investment Limited (8159.HK) Income Statement Analysis – Financial Results
Charles River Laboratories International, Inc. (CRL)
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B | 1.36B | 1.30B | 1.17B | 1.13B | 1.14B | 1.13B | 1.20B | 1.34B | 1.23B | 1.06B | 1.12B | 766.92M | 613.72M | 554.63M | 465.63M | 306.59M | 219.28M | 193.30M |
| Cost of Revenue | 2.63B | 2.51B | 2.21B | 1.85B | 1.66B | 1.43B | 1.16B | 1.03B | 832.21M | 825.00M | 770.63M | 737.45M | 740.41M | 748.66M | 773.18M | 832.78M | 752.44M | 651.78M | 693.49M | 468.35M | 380.06M | 345.65M | 298.38M | 171.45M | 120.91M | 122.55M |
| Gross Profit | 1.50B | 1.46B | 1.33B | 1.07B | 958.31M | 840.07M | 702.31M | 646.67M | 531.09M | 472.66M | 394.90M | 392.08M | 402.24M | 384.76M | 429.37M | 510.71M | 478.19M | 406.61M | 428.74M | 298.57M | 233.67M | 208.98M | 167.25M | 135.14M | 98.37M | 70.75M |
| Gross Profit Ratio | 36.39% | 36.79% | 37.70% | 36.72% | 36.56% | 37.07% | 37.81% | 38.46% | 38.96% | 36.42% | 33.88% | 34.71% | 35.20% | 33.95% | 35.70% | 38.01% | 38.86% | 38.42% | 38.20% | 38.93% | 38.07% | 37.68% | 35.92% | 44.08% | 44.86% | 36.60% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 747.86M | 665.10M | 619.92M | 528.94M | 517.62M | 443.85M | 373.45M | 367.55M | 300.41M | 269.03M | 225.70M | 208.25M | 206.14M | 262.49M | 234.00M | 230.16M | 217.49M | 180.80M | 189.54M | 121.45M | 90.24M | 83.30M | 68.32M | 51.20M | 39.77M | 34.14M |
| Other Expenses | 0.00 | 146.58M | 124.86M | 111.88M | 89.54M | 13.26M | 38.54M | 11.90M | 3.01M | 10.72M | 7.17M | -3.27M | 21.80M | 24.41M | 28.45M | 30.31M | 33.51M | 37.64M | 58.17M | 16.80M | 4.88M | 3.41M | 8.65M | 18.87M | 15.64M | 1.29M |
| Operating Expenses | 885.30M | 811.68M | 744.78M | 640.81M | 607.16M | 508.68M | 414.82M | 409.25M | 324.64M | 294.99M | 243.50M | 226.32M | 227.94M | 286.89M | 262.44M | 260.47M | 251.00M | 218.43M | 247.72M | 138.24M | 95.11M | 86.72M | 76.97M | 70.07M | 55.41M | 35.43M |
| Cost & Expenses | 3.51B | 3.33B | 2.95B | 2.49B | 2.27B | 1.93B | 1.57B | 1.44B | 1.16B | 1.12B | 1.01B | 963.77M | 968.34M | 1.04B | 1.04B | 1.09B | 1.00B | 870.21M | 941.21M | 606.59M | 475.17M | 432.36M | 375.35M | 241.52M | 176.31M | 157.98M |
| Interest Income | 5.20M | 780.00K | 652.00K | 834.00K | 1.52M | 812.00K | 690.00K | 1.31M | 1.04M | 1.15M | 730.00K | 589.00K | 1.35M | 1.19M | 1.78M | 8.69M | 9.68M | 6.84M | 3.93M | 3.29M | 0.00 | 2.12M | 1.49M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 136.71M | 59.29M | 73.91M | 86.43M | 60.88M | 63.77M | 29.78M | 27.71M | 15.07M | 11.95M | 20.97M | 33.34M | 41.23M | 34.09M | 21.68M | 14.01M | 14.83M | 193.24M | 22.62M | 8.65M | 6.56M | 27.34M | 27.28M | 67.35M | 8.28M | 0.00 |
| Depreciation & Amortization | 314.12M | 303.87M | 265.54M | 234.92M | 198.10M | 161.78M | 131.16M | 126.66M | 24.23M | 25.96M | 17.81M | 18.07M | 21.80M | 24.41M | 28.45M | 30.31M | 88.92M | 85.13M | 104.64M | 48.18M | 31.12M | 25.73M | 28.58M | 18.87M | 15.64M | 10.90M |
| EBITDA | 1.03B | 1.04B | 854.29M | 759.15M | 581.73M | 507.23M | 457.89M | 377.29M | 305.38M | 285.99M | 255.54M | 244.36M | 260.48M | -205.15M | 263.20M | -355.82M | 321.81M | 273.30M | 274.81M | 210.64M | 138.55M | 147.99M | 90.28M | 83.93M | 58.61M | 46.22M |
| EBITDA Ratio | 24.99% | 24.80% | 23.17% | 26.28% | 21.48% | 18.11% | 19.82% | 17.39% | 16.92% | 15.69% | 14.52% | 16.28% | 17.16% | 10.79% | 16.07% | 73.43% | 25.80% | 25.73% | 25.47% | 27.09% | 27.52% | 26.46% | 25.42% | 27.02% | 25.82% | 23.94% |
| Operating Income | 617.26M | 650.98M | 589.86M | 432.73M | 351.15M | 331.38M | 287.50M | 237.42M | 206.45M | 177.67M | 151.40M | 165.77M | 174.31M | -298.51M | 166.93M | -449.76M | 227.19M | 188.17M | 181.02M | 160.32M | 138.55M | 122.27M | 90.28M | 65.06M | 42.96M | 35.33M |
| Operating Income Ratio | 14.95% | 16.37% | 16.66% | 14.80% | 13.40% | 14.62% | 15.48% | 14.12% | 15.14% | 13.69% | 12.99% | 14.68% | 15.25% | -26.34% | 13.88% | -33.48% | 18.46% | 17.78% | 16.13% | 20.90% | 22.58% | 22.04% | 19.39% | 21.22% | 19.59% | 18.27% |
| Total Other Income/Expenses | -35.98M | -27.99M | -109.15M | 14.39M | -47.07M | -49.70M | 8.67M | -14.50M | -11.02M | -75.00K | -13.07M | -36.02M | -41.64M | -35.57M | -17.82M | -10.14M | -9.77M | -11.61M | -17.13M | -9.86M | -5.92M | -37.75M | -27.78M | -39.35M | -10.28M | 507.00K |
| Income Before Tax | 581.28M | 622.99M | 480.71M | 447.11M | 304.08M | 281.68M | 296.96M | 222.92M | 195.43M | 177.60M | 138.33M | 129.75M | 132.66M | -334.08M | 149.11M | -461.01M | 217.42M | 176.56M | 160.41M | 152.53M | 132.63M | 114.40M | 69.48M | 25.71M | 32.69M | 35.83M |
| Income Before Tax Ratio | 14.08% | 15.67% | 13.58% | 15.29% | 11.60% | 12.43% | 15.99% | 13.26% | 14.33% | 13.69% | 11.87% | 11.49% | 11.61% | -29.48% | 12.40% | -34.31% | 17.67% | 16.68% | 14.29% | 19.89% | 21.61% | 20.63% | 14.92% | 8.39% | 14.91% | 18.54% |
| Income Tax Expense | 100.91M | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M | 171.37M | 66.84M | 43.39M | 47.67M | 32.91M | 27.63M | 17.14M | 23.00K | 39.73M | 61.94M | 59.40M | 49.74M | 16.58M | 61.16M | 51.06M | 43.57M | 27.10M | 7.84M | 15.56M | 14.12M |
| Net Income | 474.62M | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M | 123.36M | 154.77M | 149.31M | 126.70M | 102.83M | 97.30M | 109.57M | -336.67M | 114.44M | -521.84M | 154.41M | -55.78M | 142.00M | 89.79M | 80.15M | 50.13M | 35.41M | -11.22M | 17.12M | 23.38M |
| Net Income Ratio | 11.49% | 12.23% | 11.04% | 12.46% | 9.61% | 9.99% | 6.64% | 9.20% | 10.95% | 9.76% | 8.82% | 8.61% | 9.59% | -29.70% | 9.52% | -38.84% | 12.55% | -5.27% | 12.65% | 11.71% | 13.06% | 9.04% | 7.60% | -3.66% | 7.81% | 12.09% |
| EPS | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 | 3.21 | 2.72 | 2.15 | 2.03 | 2.16 | -5.38 | 1.75 | -7.76 | 2.31 | -0.81 | 2.04 | 1.81 | 1.76 | 1.12 | 0.86 | -0.40 | 0.86 | 2.27 |
| EPS Diluted | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 | 3.23 | 3.13 | 2.66 | 2.12 | 2.01 | 2.14 | -5.38 | 1.74 | -7.76 | 2.25 | -0.80 | 1.96 | 1.67 | 1.64 | 1.06 | 0.80 | -0.35 | 0.86 | 2.27 |
| Weighted Avg Shares Out | 51.23M | 50.81M | 50.29M | 49.55M | 48.73M | 47.95M | 47.48M | 47.01M | 46.50M | 46.63M | 47.74M | 47.91M | 50.82M | 62.56M | 65.37M | 67.27M | 66.96M | 68.87M | 69.61M | 49.60M | 45.54M | 44.76M | 41.17M | 28.06M | 19.82M | 10.29M |
| Weighted Avg Shares Out (Dil) | 51.45M | 51.30M | 51.43M | 50.61M | 49.69M | 49.02M | 48.56M | 47.96M | 47.63M | 47.56M | 48.49M | 48.41M | 51.32M | 62.56M | 65.64M | 67.27M | 68.74M | 69.73M | 72.45M | 56.05M | 48.87M | 47.29M | 44.26M | 32.07M | 19.82M | 10.29M |
Charles River (CRL) Banks on RMS Growth Amid Competition
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The 7 Best Growth Stocks to Buy in May 2024
Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
ICLR vs. CRL: Which Stock Is the Better Value Option?
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Source: https://incomestatements.info
Category: Stock Reports